This is not the most recent version of the article. View current version (5 OCT 2011)

Intervention Protocol

Cannabinoids for multiple sclerosis

  1. Joep Killestein1,*,
  2. Chris Polman1,
  3. Bernard MJ Uitdehaag2

Editorial Group: Cochrane Multiple Sclerosis Group

Published Online: 21 JAN 2009

Assessed as up-to-date: 26 OCT 2002

DOI: 10.1002/14651858.CD003981

Database Title

Additional Information

How to Cite

Killestein J, Polman C, Uitdehaag BMJ. Cannabinoids for multiple sclerosis (Protocol). Cochrane Database of Systematic Reviews 2002, Issue 4. Art. No.: CD003981. DOI: 10.1002/14651858.CD003981.

Author Information

  1. 1

    VU University Medical Center, Department of Neurology, Amsterdam, Netherlands

  2. 2

    VU University Medical Center, Departments of Neurology and Clinical Epidemiology and Biostatistics, Amsterdam, Netherlands

*Joep Killestein, Department of Neurology, VU University Medical Center, PO Box 7057, Amsterdam, 1007 MB, Netherlands. j.killestein@vumc.nl.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 21 JAN 2009

SEARCH

ARTICLE TOOLS

This is not the most recent version of the article.View current version (05 Oct 2011)

View Full Article (HTML) Full (99K)
 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

The objective of this review is to assess safety and efficacy of cannabinoids in multiple sclerosis patients.
The primary question is whether cannabinoids are more effective than placebo or other treatment in decreasing MS-related symptoms
(i.e. spasticity, pain, bladder dysfunction, tremor, fatigue, nystagmus and ataxia) and increasing quality of life.
The secondary question is whether cannabinoids are more effective than placebo or other treatment in decreasing the number of patients who experience clinical relapses or disease progression.

View Full Article (HTML) Full (99K)